Bendamustin
Sponsors
University Hospital Tuebingen, ECOG-ACRIN Cancer Research Group, Meir Medical Center, Ruijin Hospital, The Lymphoma Academic Research Organisation
Conditions
Classical Hodgkin LymphomaCytopeniaFollicular LymphomaLymphomaLymphoma, Mantle-CellSarcoma, Soft Tissue
Phase 1
CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma
Not yet recruitingNCT07575893
Start: 2026-10-01End: 2032-12-01Target: 12Updated: 2026-05-20
Autoimmune Cytopenia Elimination by Chimeric Antigen Receptor T-cell Therapy
Not yet recruitingNCT07790575
Start: 2026-09-01End: 2041-07-01Target: 16Updated: 2026-08-27
Phase 2
Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS)
CompletedNCT00204620
Start: 2002-03-31End: 2006-12-31Target: 28Updated: 2007-04-20
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
CompletedNCT01216683
Start: 2011-02-09End: 2019-12-02Updated: 2023-06-29
Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status
NCT04934930
Start: 2020-01-29End: 2025-08-01Target: 40Updated: 2021-06-22
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
RecruitingNCT06136351
Start: 2023-11-15End: 2027-11-01Target: 23Updated: 2023-11-29